Form 4: Baker Bros. Boosts Celcuity Stake with $9.6M Share Purchase

Baker Bros. Advisors and its principals, Felix and Julian Baker, reported significant purchases of Celcuity Inc. common stock totaling 170,100 shares for approximately $9.6 million.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix Baker, and Julian Baker, who are 10% owners and directors of Celcuity Inc. (CELC), reported the acquisition of 170,100 shares of common stock.
• The transactions occurred on September 8, 2025, through various funds advised by Baker Bros. Advisors.
• Shares were purchased at weighted average prices of $56.22 and $58.0236 per share.
• The total value of the acquired shares is approximately $9,571,918.56.
• Following these transactions, the reporting persons indirectly beneficially own a total of 7,915,792 shares of Celcuity Inc. common stock.

Sentiment

Score: 8

Explanation: The significant purchase of common stock by Baker Bros. Advisors LP and its principals, who are also 10% owners and directors, indicates strong confidence in Celcuity Inc.'s future prospects and valuation.

Positives

• Significant insider buying by a major institutional investor and company directors indicates strong confidence in Celcuity Inc.'s future prospects and valuation.
• The substantial investment by Baker Bros. Advisors, a prominent biotech-focused fund, suggests a positive outlook on the company's strategic direction and potential for growth.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance from the company. However, the significant insider buying by a major investor can be interpreted as a strong vote of confidence in the company's future prospects.

Industry Context

Baker Bros. Advisors is a highly respected investment firm specializing in the biotechnology sector. Their increased stake in Celcuity Inc., a biotech company, signals continued confidence in the company's pipeline, market position, or strategic direction within the broader life sciences industry.

Comparison to Industry Standards

• The filing does not contain specific comparable company or project data to assess against global benchmarks.
• However, substantial insider buying by a prominent biotech investment firm and its principals, who are also directors and 10% owners, is widely regarded as a strong positive indicator within the investment community, signaling high conviction in the company's valuation and strategic direction.

Related Party Transactions

• The reported transactions involve the acquisition of common stock by Baker Bros. Advisors LP and its principals, who are 10% owners and directors of Celcuity Inc., making these related party transactions under SEC reporting rules for insiders.

Stakeholder Impact

• Shareholders may view this significant insider buying as a strong positive signal, potentially increasing investor confidence and demand for Celcuity Inc. stock.
• The increased stake by a major institutional investor could provide greater stability and long-term focus for the company.

Key Dates

Recommendation

The significant purchase of Celcuity Inc. common stock by Baker Bros. Advisors, a prominent biotech investor, and its principals, who also serve as directors and 10% owners, signals strong conviction in the company's valuation and future prospects. This substantial insider buying activity is a positive indicator for investors, suggesting potential upside.

Keywords

Celcuity Inc., CELC, Baker Bros. Advisors, Insider Buying, Form 4, Stock Purchase, Biotech Investment, 10% Owner, Director, Equity Acquisition